Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check3 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0 label. This indicates a minor software update to the page's versioning without altering the study content.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedNew navigation/help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment status was updated to No longer looking for participants; the edition label updated to Revision: v3.6.0 and the Intervention/Treatment heading formatting was standardized.SummaryDifference0.5%

- Check25 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling an updated version of the page rendering. This does not reflect changes to the study details or content.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was removed, indicating a software version update on the page. The underlying study content and navigation remain unchanged.SummaryDifference0.1%

- Check60 days agoChange DetectedThe study record's revision label was updated from v3.5.2 to v3.5.3, indicating a new version of the entry. This update reflects a metadata revision rather than changes to the study content, eligibility, or results.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.